NNVC NanoViricides, Inc. featured news, full reports, and detailed charts
NanoViricides, Inc. (NNVC/NNVC.OB) Wrap Up:
NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. It has licenses in perpetuity to develop drugs for the treatment of human viral diseases, such as human immunodeficiency virus, Hepatitis B Virus, Hepatitis C Virus (HCV), Herpes Simplex Virus, Rabies, Influenza, and Asian Bird Flu Virus. The company’s products under development include FluCide-I for the treatment of common influenzas and avian influenza H5N1; AviFluCide-I against H5N1, the avian influenza strain; FluCide-HP against highly pathogenic avian influenza viruses; RabiCide-I, a nanoviricide ...www.nanoviricides.com
4 Employees
Founded in 2005
NanoViricides, Inc. (NNVC:OTC Bulletin Board Market)
LAST $0.92 USD
CHANGE TODAY +0.039 4.43%
VOLUME 245.5K
As of 3:59 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of NanoViricides, Inc. (NNVC)
|
OPEN
$0.87
|
PREVIOUS CLOSE
$0.88
|
|
|
DAY HIGH
$0.92
|
DAY LOW
$0.87
|
|
|
52 WEEK HIGH
04/27/09 - $1.29
|
52 WEEK LOW
11/20/08 - $0.39
|
|
|
MARKET CAP
115.1M
|
AVERAGE VOLUME 3 mo
214.1K
|
|
|
DILUTED EPS TTM
$-0.02
|
SHARES OUTSTANDING
125.3M
|
|
|
NNVC Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
NNVC Top Compensated Officers
Dr. Eugene Seymour MD, MPH
Chief Executive Officer, Chief Financial Offi...
Age: 68
Total Annual Compensation: $250.0K
Dr. Anil R. Diwan Ph.D.
Chairman and President
Age: 50
Total Annual Compensation: $252.0K
Executives, Board Directors
Compensation as of Fiscal Year 2009.
Key developments for NanoViricides, Inc. (NNVC)
NanoViricides, Inc. - Conference Presentation Call
11/16/2009
NanoViricides, Inc. - Conference Presentation Calls
NanoViricides, Inc. announced delayed 10-Q filing
11/16/2009
On 11/16/2009, NanoViricides, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
NanoViricides, Inc. - Conference Presentation Call
11/9/2009
To review the company's recent in vivo studies against influenza
NNVC Competitors
| Company | Last | Change |
| BioCryst Pharmaceuticals INC | $9.55 USD | -0.85 |
| InterMune Inc | $10.79 USD | -0.09 |
| Pharmasset Inc | $19.66 USD | +0.06 |
| Valeant Pharmaceuticals International | $33.28 USD | -0.38 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | NNVC | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 44.4x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
NNVC |
||
|
NNVC transactions
| Type Date |
Target |
|
Private Placement
July 7, 2009 |
-- |
More Recent News About NanoViricides, Inc.
Would you like to leave a comment about NanoViricides, Inc. NNVC/NNVC.OB
Find out what social network information about NanoViricides, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides NanoViricides, Inc. there is more great information available at Realpennies.com